• Top Eminent Healthcare swung to a profit attributable to shareholders of HK$1.37 million from a loss a year earlier.
• Revenue climbed 65% to HK$74.51 million, driven by stronger healthcare product sales and wider B2B and B2C channel reach.
• Profit before tax returned to profit at HK$2.09 million, helped by improved operating leverage and no repeat of prior one-off professional fees.
• Operating cash flow fell 98% to HK$118,000, while cash and bank balances rose to HK$212.8 million from year-end.
• Management kept its focus on expanding Chinese medicines and healthcare products, investing in marketing and customer acquisition, and exploring wellness supplements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Top Eminent Healthcare Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260908-12324246), on September 08, 2026, and is solely responsible for the information contained therein.